Mouni Pavitra: ఆ లక్ష మీరేమైనా ఇచ్చారా- బుల్లితెర నటి పవిత్ర ఆగ్రహం- మౌనీ రాయ్ ప్లాస్టిక్ సర్జరీ ట్రోలింగ్‌పై కౌంటర్లు

భారతదేశం, మే 1 -- Pavitra Punia Defends Mouni Roy Plastic Surgery Trolling: బాలీవుడ్ హాట్ బ్యూటీ మౌనీ రాయ్‌పై జరుగుతున్న ప్లాస్టిక్ సర్జరీ ట్రోలింగ్‌పై బుల్లితెర నటి పవిత్ర పునియా తీవ్రస్థాయిలో విరుచు... Read More

PREMIUM TIMES to honour outstanding journalists at annual staff awards

Nigeria, May 1 -- Nigeria's foremost accountability journalism platform, PREMIUM TIMES, will hold its combined 3rd and 4th annual staff award ceremony this weekend. The event will celebrate outstandin... Read More

Esperion Therapeutics Stock Soars 56% On Acquisition Deal

India, May 1 -- Esperion Therapeutics, Inc. (ESPR) shares surged 56.25 percent to $3.1250 on Friday, gaining $1.1250, after the company announced a definitive acquisition agreement. The stock is curr... Read More

2027 KTM 450 Rally Replica: 5 things enthusiasts should know

India, May 1 -- KTM recently brought back one of its most extreme production bikes for 2027, but buyers will need to act fast. The KTM 450 Rally Replica is being built in very small numbers and is aim... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

Singapore, May 1 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and E... Read More

Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

Singapore, May 1 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and T... Read More

Singapore Clinical Trial: A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)

Singapore, May 1 -- The Health Sciences Authority received information related to the study titled 'A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nera... Read More

Singapore Clinical Trial: A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY4302814 in Healthy Participants

Singapore, May 1 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending Do... Read More

Singapore Clinical Trial: A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Singapore, May 1 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib... Read More

Singapore Clinical Trial: A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Investigator’s Choice of TKI Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Singapore, May 1 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined... Read More

• ««
• «
• 18513
• 18514
• 18515
• 18516
• 18517
• 18518
• 18519
• 18520
• 18521
• 18522
• »
• »»